Evidence map›Paper›PMID 28723413›Full record

ReviewPharmacology & therapeutics2018

Multifunctional molecule ERp57: From cancer to neurodegenerative diseases.

Aubryanna Hettinghouse, Ronghan Liu, Chuan-Ju Liu

Open access · greenAbstract readReview
In one paragraph

Review in Pharmacology & therapeutics, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 56 papers.

0numbers the graph read from it
0cells of the map it votes in
56citing papers in PubMed
3.5field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

56 citing papers in PubMed, 104 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Analysis of Punicalin and Punicalagin Interaction with PDIA3 and PDIA1.International journal of molecular sciences · 2024
    Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

Aubryanna HettinghouseDepartment of Orthopaedic Surgery, New York University Medical Center, New York, NY 10003, USA.
Ronghan LiuDepartment of Orthopaedic Surgery, New York University Medical Center, New York, NY 10003, USA.
Chuan-Ju LiuDepartment of Orthopaedic Surgery, New York University Medical Center, New York, NY 10003, USA; Department of Cell Biology, New York University School of Medicine, New York, NY 10016, USA. Electronic address: chuanju.liu@med.nyu.edu.
New York University · USColumbia University Irving Medical Center · US

Funding

The immunological mechanism of PGRNs anti-inflammatory effect - Renewal - 1R01AR062207 · NIAMS · YALE UNIVERSITY · PI Chuanju Liu · 2012 to 2026
$5.6M
The Role of PGRN Growth Factor in Osteoarthritis. - Renewal - 1 - Revision - 2R01AR061484 · NIAMS · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI LIU, CHUANJU · 2011 to 2020
$4.8M
Progranulin: A Novel Gene in Gaucher DiseasesR01NS103931 · NINDS · YALE UNIVERSITY · PI Chuanju Liu, Ying Sun · 2017 to 2026
$4.3M
NIAMS NIH HHS R01 AR061484NIAMS NIH HHS R01 AR062207NINDS NIH HHS R01 NS103931
6 · The paper itself

Abstract

The protein disulfide isomerase (PDI) gene family is a protein family classically characterized by endoplasmic reticulum (ER) localization and isomerase and redox activity. ERp57, a prominent multifunctional member of the PDI family, is detected at various levels in multiple cellular localizations outside of the ER. ERp57 has been functionally linked to a host of physiological processes and numerous studies have demonstrated altered expression and aberrant functionality of ERp57 in association with diverse pathological states. Here, we summarize available knowledge of ERp57's functions in subcellular compartments and the roles of dysregulated ERp57 in various diseases toward an emphasis on the potential utility of therapeutic development of ERp57.

Indexed as

AnimalsHumansNeoplasmsNeurodegenerative DiseasesProtein Disulfide-IsomerasesPDIA3 protein, humanProtein Disulfide-IsomerasesCancerClinical biomarkerERp57/PDIA3Immune responseMusculoskeletal systemNeurodegeneration

Identifiers

PMID28723413
PMCPMC5743601
OpenAlexW2735892656

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.